Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
基本信息
- 批准号:8095442
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-15 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This project, which builds on our recent observations of regulation of Fas death receptor, takes us to a new area of research, the analysis of liver cells, where Fas plays a critical role mediating liver disorders. Death receptors have key roles in numerous cell death/proliferation decisions. More specifically, the Fas death receptor plays a pivotal role in liver tissue to determine the outcomes of challenges induced by cell stress due to infection and toxins. The Fas system is an important cell elimination system that has several established functions, including the elimination of autoreactive lymphocytes, infected and defective cells and cells damaged by chemotherapy and irradiation. Without the Fas system, for example, in Fas -/- cells, many clinical chemotherapies and ionizing radiation are no longer effective in eradicating cells. Given the common expression of Fas, the common inability to eliminate some cells that express Fas, we suspect Fas to be under tight control. While Fas activation serves as a clinically beneficial mediator of chemotherapy, inadvertent Fas signaling can perpetuate liver damage and death. In this project we searched for potential binding regulators of Fas and identified a tumor suppressor protein promyelocytic leukemia protein (PML), which is associated with enhanced apoptosis. We chose to test the dominant-negative PMLRARa because its phenotype is easier to visualize. We found that PMLRARa (and PML) binds to Fas and potently blocks apoptosis in cells. When express in mouse liver, PMLRARa effectively protects mice from death induced by a lethal dose of agonistic anti-Fas antibody. The B-box domain of PML is necessary for binding to Fas, suggesting that PML and PMLRARa use this site to bind Fas. A model of opposing effects of PML and PMLRARa on regulation of transforming growth factor 2 receptor (TGF2R) has been established and we suspect that Fas operates in a similar model. Our hypothesis is that PML positively regulates Fas signaling, which plays a critical role in death and proliferation decisions. We will use PML dominant-negative mutant PMLRARa as a probe to characterize the blocking effects on Fas. We anticipate that PML will express have Fas-promoting effects and will explain the widely known apoptosis enhancement effect of PML. Our hypothesis is that PML is a binding regulator of Fas and this interaction can be modulated to preserve liver tissue function. The long-term goal of this project is to understand apoptosis regulation of liver cells to reverse liver pathology driven by the Fas receptors.
PUBLIC HEALTH RELEVANCE: The Fas system is an important cell elimination system that has several established functions, including the elimination of autoreactive lymphocytes and infected and defective cells and cells damaged by chemotherapy and irradiation. We have identified promyelocytic leukemia protein as a binding and potential key regulator of Fas signaling. This project will characterize the binding with Fas and demonstrate how Fas is regulated in liver cells and in mice; thus by showing the site of regulation of Fas, we will be able to identify an effective therapeutic approach for liver disorders driven by Fas signaling.
描述(由申请人提供):该项目建立在我们最近对FAS死亡受体调节的观察结果的基础上,将我们带入了一个新的研究领域,即对肝细胞的分析,其中FA在其中介导了肝脏疾病的关键作用。死亡受体在许多细胞死亡/增殖决策中具有关键作用。更具体地说,FAS死亡受体在肝组织中起关键作用,以确定因感染和毒素引起的细胞应激引起的挑战结果。 FAS系统是一个重要的细胞消除系统,具有多个已建立的功能,包括消除自动反应性淋巴细胞,感染和缺陷的细胞以及受化学疗法和辐照损害的细胞。如果没有FAS系统,例如在FAS - / - 细胞中,许多临床化疗和电离辐射不再有效地消除细胞。鉴于FA的共同表达,通常无法消除某些表达FA的细胞,我们怀疑FAS受到严格的控制。尽管FAS激活是化学疗法的临床有益介质,但无意的FAS信号传导可使肝脏损害和死亡永存。在这个项目中,我们搜索了FAS的潜在结合调节剂,并确定了肿瘤抑制蛋白临床细胞性白血病蛋白(PML),该蛋白(PML)与增强的凋亡有关。我们选择测试主要的阴性PMLRARA,因为它的表型易于可视化。我们发现PMLRARA(和PML)与FAS结合并有效地阻断细胞中的凋亡。当在小鼠肝脏中表达时,PMLRARA有效保护小鼠免受致命剂量激动剂抗FAS抗体诱导的死亡。 PML的B盒域对于与FAS结合是必需的,这表明PML和PMLRARA使用此位点结合FAS。已经建立了PML和PMLARA对转化生长因子2受体(TGF2R)调节的相反作用的模型,我们怀疑FAS在类似的模型中运行。我们的假设是,PML积极调节FAS信号,这在死亡和增殖决策中起着至关重要的作用。我们将使用PML显性阴性突变体PMLRARA作为表征对FAS的阻塞效应的探针。我们预计PML将表达具有FAS的促进作用,并将解释PML的广为已知的凋亡增强作用。我们的假设是PML是FAS的结合调节剂,可以调节这种相互作用以保留肝组织功能。该项目的长期目标是了解肝细胞的凋亡调节,以逆转由FAS受体驱动的肝脏病理学。
公共卫生相关性:FAS系统是一个重要的细胞消除系统,具有多个已建立的功能,包括消除自动反应性淋巴细胞,感染和有缺陷的细胞以及通过化学疗法和辐照损害的细胞。我们已经将临时细胞性白血病蛋白确定为FAS信号的结合和潜在的关键调节剂。该项目将表征与FAS的结合,并证明在肝细胞和小鼠中如何调节FAS;因此,通过显示FAS调节部位,我们将能够确定FAS信号驱动的肝脏疾病的有效治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
FELIPE SAMANIEGO的其他基金
Cancer Cell Overexpression of Death Receptor Modulator
癌细胞过度表达死亡受体调节剂
- 批准号:83886228388622
- 财政年份:2012
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Cancer Cell Overexpression of Death Receptor Modulator
癌细胞过度表达死亡受体调节剂
- 批准号:85347268534726
- 财政年份:2012
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
- 批准号:83333688333368
- 财政年份:2011
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
PMLRARα 和 PML 直接调节体内 Fas 介导的细胞凋亡
- 批准号:81000468100046
- 财政年份:2011
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
- 批准号:85106368510636
- 财政年份:2011
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
PMLRARα 和 PML 直接调节体内 Fas 介导的细胞凋亡
- 批准号:82450308245030
- 财政年份:2011
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Targeting Fas Inhibitors in Cancer Therapy
癌症治疗中的靶向 Fas 抑制剂
- 批准号:81110868111086
- 财政年份:2010
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Targeting Fas Inhibitors in Cancer Therapy
癌症治疗中的靶向 Fas 抑制剂
- 批准号:79940537994053
- 财政年份:2010
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
PKB/Akt Activation and Cell Survival with HIV-1 Tat
HIV-1 Tat 的 PKB/Akt 激活和细胞存活
- 批准号:69475846947584
- 财政年份:2005
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
PKB/Akt Activation and Cell Survival with HIV-1 Tat
HIV-1 Tat 的 PKB/Akt 激活和细胞存活
- 批准号:70528847052884
- 财政年份:2005
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
相似国自然基金
分泌IL-6纳米抗体的重组枯草芽孢杆菌通过CXCL10/CXCR3轴介导CD4+效应T细胞凋亡减轻IBD肠道炎症的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
分泌IL-6纳米抗体的重组枯草芽孢杆菌通过CXCL10/CXCR3轴介导CD4+效应T细胞凋亡减轻IBD肠道炎症的机制研究
- 批准号:82200581
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
抗CD4自身抗体介导CD4+T细胞凋亡在艾滋病免疫无应答患者中的机制及治疗作用
- 批准号:
- 批准年份:2021
- 资助金额:54 万元
- 项目类别:面上项目
抗HuD抗体引起肠易激综合征肠神经元凋亡机制及靶向干预研究
- 批准号:82100568
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
抗HuD抗体引起肠易激综合征肠神经元凋亡机制及靶向干预研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:1063725110637251
- 财政年份:2023
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡的调节性坏死途径的辐射缓解剂
- 批准号:1083823210838232
- 财政年份:2023
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence
通过 DSTYK 沉默增强三阴性乳腺癌的化疗效果
- 批准号:1065702110657021
- 财政年份:2023
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Prohibiting Cell Death in Human Keratocytes: New Insights for Non-surgical Keratoconus Treatment
抑制人角膜细胞的细胞死亡:非手术圆锥角膜治疗的新见解
- 批准号:1072043110720431
- 财政年份:2023
- 资助金额:$ 19.75万$ 19.75万
- 项目类别:
Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure
用单克隆抗体靶向心脏中的核酸外切酶以预防梗死后心力衰竭
- 批准号:1071146910711469
- 财政年份:2023
- 资助金额:$ 19.75万$ 19.75万
- 项目类别: